Larimar Therapeutics, Inc. Common Stock
$3.93
Market Cap
$408.26M
Shares Outstanding
103.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 29, 2020
Round Lot
100
Locale
US
Day Open
$3.93
Day High
$3.97
Day Low
$3.83
Volume
1.96M
VWAP
$3.90
Prev Close
$3.91
Transactions
--
Acc. Volume
--
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Larimar Therapeutics, Inc. Common Stock (LRMR) closed the 2026-09-16 session at $3.93, up 0.51% versus the previous close (+0.02). The stock opened at $3.93 and traded between $3.83 and $3.97 during that session. Session trading volume was 2.0M shares. The volume-weighted average price (VWAP) is $3.90.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Larimar Therapeutics, Inc. Common Stock has a market capitalization of $408.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. LRMR is listed on the XNAS exchange. The company employs approximately 71 people. Larimar Therapeutics, Inc. Common Stock is headquartered in BALA CYNWYD, PA. The recorded listing date is 2020-05-29.
On this page you can find market LRMR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.